⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2140050 | 0.95 | — | — | |
| SCHEMBL25523 | 0.94 | — | — | |
| SCHEMBL10527930 | 0.89 | — | — | |
| Phosphine SCHEMBL3457955 | 0.89 | — | — | |
| SCHEMBL5484935 | 0.89 | — | — | |
| SCHEMBL11054053 | 0.89 | — | — | |
| Hydrogen Sulfide SCHEMBL6899977 | 0.89 | — | — | |
| SCHEMBL5934110 | 0.89 | — | — | |
| SCHEMBL21044699 | 0.89 | — | — | |
| Potassium SCHEMBL11837016 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273933-B1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| US-20040185491-A1 | Methods for synthesis of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| EP-1066308-A4 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-07-02 | — | — | EP | claimed |
| US-20020142980-A1 | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | RIBOZYME PHARMACEUTICALS INC. | 2002-10-03 | — | — | US | claimed |
| EP-1066308-A1 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-10 | — | — | EP | claimed |
| WO-1999043694-A1 | IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-02 | — | — | WO | claimed |
| EP-0649467-B1 | SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS | HYBRIDON INC (US) | 1998-09-16 | — | — | EP | claimed |
| EP-0652890-B1 | OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES | HYBRIDON INC (US) | 1998-01-14 | — | — | EP | claimed |
| US-20240084307-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2024-03-14 | — | — | US | disclosed |
| US-11739332-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-08-29 | — | — | US | disclosed |
| US-20220025376-A1 | ANTISENSE OLIGOMERS TARGETING PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2022-01-27 | — | — | US | disclosed |
| US-11155816-B2 | Oligonucleotide conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-10-26 | — | — | US | disclosed |
| US-11091764-B2 | Antisense oligomers targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-08-17 | — | — | US | disclosed |
| US-20210238601-A1 | Oligonucleotide Conjugates | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2021-08-05 | — | — | US | disclosed |
| US-5929226-A | THREE OR MORE BUT NOT ALL NUCLEOTIDES ARE CONNECTED WITH METHYLPHOSPHONOTHIOATE LINKAGES WHERE SULFUR IS NOT BRIDGING ATOM; INCREASED RESISTANCE TO NUCLEASES, INCREASED DUPLEX STABILITY | HYBRIDON, INC. (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0652890-B1 | OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES | HYBRIDON INC (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0793718-A1 | MOLECULAR TAGGING SYSTEM | LYNX THERAPEUTICS, INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996012014-A1 | MOLECULAR TAGGING SYSTEM | LYNX THERAPEUTICS, INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0652890-A1 | OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES | HYBRIDON, Inc. (US) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002499-A1 | OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES | HYBRIDON, INC. (US) | 1994-02-03 | — | — | WO | disclosed |